New Haven, United States
Halda Therapeutics, founded in 2018, is a pioneering player in the Biotechnology industry, with a focus on oncology. Located in New Haven, CT, the company operates from its headquarters and cutting-edge labs in Science Park. Halda specializes in developing RIPTAC™ therapeutics, a novel drug modality designed to target cancer and conquer drug resistance, diverging from traditional treatments that rely on oncogenic disease drivers. This innovative ‘hold and kill’ mechanism facilitates selective cancer cell targeting, aiming to eradicate cancer cells by disrupting essential protein functions.
Halda's distinct approach has led to a robust pipeline tailored for major cancer types, offering hope to patients battling drug-resistant forms of the disease. With its slogan, “Taking Hold, Conquering Cancer,” Halda embodies a commitment to collaboration and creativity in advancing drug discovery. The company's recent $3.05B acquisition investment by Johnson & Johnson in November 2025 underscores its potential as a significant innovator in cancer therapeutics.
Cyclacel Pharmaceuticals, Inc.
